Investors

Press Releases

Date Title View
Toggle Summary Baxalta and Momenta Announce Initiation of Pivotal Clinical Trial for M923, a Biosimilar Version of HUMIRA (adalimumab)
Pivotal Trial of M923 in Chronic Plaque Psoriasis to Support E.U. and U.S. Registrations
View HTML
Toggle Summary Baxalta and Momenta Announce M923, a Proposed HUMIRA (adalimumab) Biosimilar, Met Primary Endpoint in Pharmacokinetic Study
BANNOCKBURN, Ill. and CAMBRIDGE, Mass. , Dec. 21, 2015 (GLOBE NEWSWIRE) -- Baxalta Incorporated (NYSE:BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), today announced that M923 met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study.
View HTML
Toggle Summary Baxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On Biologics
DEERFIELD, Ill. & CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars.
View HTML
Toggle Summary First Patient Dosed With M402 in Phase 1/2 Clinical Trial in Metastatic Pancreatic Cancer
Dosing of First Patient Represents Important Milestone in Expanding Pipeline of Novel Oncology Drug Candidates
View HTML
Toggle Summary Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
--Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL--              --Momenta to host a conference call for its investors today at 4:30 PM ET -- CAMBRIDGE, Mass. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.
View HTML
Toggle Summary Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 CAMBRIDGE, Mass. , HERTFORDSHIRE, United Kingdom and PITTSBURGH , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL) today announced the
View HTML
Toggle Summary Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio
View HTML
Toggle Summary Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that M834, a proposed biosimilar of ORENCIA (abatacept), did not meet its primary pharmacokinetic
View HTML
Toggle Summary Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
CAMBRIDGE, Mass. , Nov. 13, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that it has put a temporary hold on patient enrollment in its ongoing Phase 2 portion of the trial, "A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402
View HTML
Toggle Summary Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
CAMBRIDGE, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating
View HTML